Conjunctivitis Treatment Global Market Report 2024

The conjunctivitis treatment market size has grown steadily in recent years. It will grow from $4.49 billion in 2023 to $4.7 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth observed in the historical period can be attributed to several factors. These include the globalization of eye care services, which expanded their reach and accessibility across different regions, increased affordability and availability of treatments, a growing demand for combination therapies that offer comprehensive solutions, innovations in anti-inflammatory treatments providing improved care options, and advancements in eye care infrastructure contributing to enhanced services and accessibility for patients.

The conjunctivitis treatment market size is expected to see steady growth in the next few years. It will grow to $5.48 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be attributed to several key factors. These include an increased emphasis on preventive healthcare measures aimed at minimizing the occurrence of conjunctivitis, a rising global incidence of this condition leading to higher demand for treatment, the growth of healthcare awareness and improved access to medical services, an increase in environmental allergens contributing to a higher prevalence of conjunctivitis, and the expanding aging population more susceptible to eye-related issues. Major trends expected in this period encompass regulatory shifts affecting treatment approvals and standards, a heightened focus on enhancing patient comfort and managing symptoms effectively, the integration of artificial intelligence in the diagnosis and management of conjunctivitis, a growing demand for combination therapies providing comprehensive solutions, and an increased interest in herbal and alternative remedies for conjunctivitis treatment.

The conjunctivitis treatment market is poised for growth, fueled by the rising prevalence of conjunctivitis cases. Conjunctivitis, the inflammation of the conjunctiva, has witnessed an increase in instances, driving the demand for effective treatment options. Seeking medical attention and treatment for conjunctivitis has become more common, contributing to the growing conjunctivitis treatment market. As of June 2022, statistics from the American Medical Association indicated a higher prevalence of viral conjunctivitis compared to bacterial conjunctivitis among adults, accounting for 78% and 16%, respectively. In children, bacterial conjunctivitis was more prevalent at 71%, while viral conjunctivitis accounted for 16%. This upward trend in conjunctivitis cases emphasizes the need for treatment options, thereby bolstering the conjunctivitis treatment market.

The growth of the conjunctivitis treatment market is further augmented by an increasing geriatric population. The elderly, constituting the geriatric population, are more susceptible to various eye conditions, including conjunctivitis. Factors such as weakened immune systems, pre-existing medical conditions, and age-related changes in eye health contribute to the heightened vulnerability of the elderly to infections. According to October 2022 data from the World Trade Organization, the global population aged 60 and above increased from 1 billion to 1.4 billion in 2021. Projections for the future indicate a doubling of the world’s population of adults aged 60 and above by 2050, reaching 2.1 billion. Additionally, the number of individuals aged 80 or more is anticipated to triple between 2020 and 2050, reaching 426 million. This demographic shift toward an aging population is a significant driver for the conjunctivitis treatment market, reflecting an increased demand for treatments tailored to the specific needs of the elderly.

Product innovation stands out as a pivotal trend gaining momentum in the conjunctivitis treatment market. Leading companies within this market are strategically focusing on the development of innovative products to reinforce their market presence. A noteworthy example is Johnson & Johnson Vision Care, a US-based division specializing in eye health and vision care. In March 2022, the company secured approval from the US FDA for ACUVUE Theravision with Ketotifen, a groundbreaking drug-eluting contact lens. This novel technology integrates ACUVUE daily disposable contact lenses with a well-established antihistamine, creating an entirely new category in the market. ACUVUE Theravision with Ketotifen is specifically designed to prevent ocular itch caused by allergic conjunctivitis while offering vision correction for eligible contact lens wearers without red eyes and with up to 1.00 D of astigmatism.

Major players in the conjunctivitis treatment market are also directing their efforts toward product development and launches, particularly in the realm of ophthalmic products. This category encompasses medical and pharmaceutical products tailored for the care and treatment of the eyes and vision-related conditions. A notable illustration comes from Harrow, Inc., a US-based company specializing in ophthalmic healthcare. In July 2023, Harrow, Inc. unveiled five innovative ophthalmic products in the United States, showcasing a diverse range of solutions for various eye conditions. Notable among these products are FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, targeting steroid-responsive inflammatory eye conditions, and NATACYN (natamycin ophthalmic suspension) 5%, the only FDA-approved topical ophthalmic antifungal medication addressing fungal blepharitis, conjunctivitis, and keratitis. TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% offers a solution for inflammatory ocular conditions requiring a corticosteroid with a risk of bacterial ocular infection. VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, designated as an orphan product, serves the treatment of vernal keratoconjunctivitis in both children and adults. Lastly, ZERVIATE (cetirizine ophthalmic solution) 0.24% addresses ocular itching associated with allergic conjunctivitis. This strategic product launch highlights Harrow, Inc.'s commitment to providing diverse and targeted solutions for a spectrum of ophthalmic conditions.

In March 2022, Théa Pharma Inc., a U.S.-based pharmaceutical company specializing in eye care products, successfully acquired seven branded ophthalmic products from Akorn Operating Company LLC. The specific financial details of this transaction were not publicly disclosed. This strategic acquisition represents a significant move by Théa Pharma Inc. to reinforce its presence as a key provider of specialized eye care products tailored to meet the needs of eye care professionals across the United States. Akorn Operating Company LLC, the seller, is a pharmaceutical firm based in the U.S. and focuses on manufacturing ophthalmic solutions, injectables, and oral liquid pharmaceuticals.

Major companies operating in the conjunctivitis treatment market report are Pfizer Inc., Johnson and Johnson, AbbVie Inc., Novartis AG, Sanofi SA, Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Inc., Bausch Health Companies Inc, Santen Pharmaceuticals Co. Ltd, Lupin Limited, Allergan PLC, Alembic Pharmaceuticals Ltd, Akorn Inc., Micro Labs Ltd., Indoco Remedies Ltd., Mankind Pharma Ltd., AFT pharmaceuticals Limited, Ocular Therapeutics Inc., Sirion Therapeutics Inc., Jabs Biotech Pvt. Ltd., Atopix Therapeutics Ltd., JAWA Pharmaceuticals Pvt. Ltd., Eyevance Pharmaceuticals LLC, NicOx SA.

North America was the largest region in the conjunctivitis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the conjunctivitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the conjunctivitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drugs utilized for conjunctivitis treatment include antibiotics, antivirals, anti-allergic medications, and artificial tears. Antibiotics, specifically targeting bacterial infections, function by either eliminating bacteria or hindering their growth. They are frequently prescribed for conjunctivitis caused by bacterial agents to mitigate inflammation and eradicate the bacterial infection. These medications are applied orally or topically and are instrumental in addressing various conditions such as allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The usage of these medications spans across various end-users, including hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The conjunctivitis treatment research report is one of a series of new reports that provides conjunctivitis treatment market statistics, including the conjunctivitis treatment industry's global market size, regional shares, competitors with a conjunctivitis treatment market share, detailed conjunctivitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the conjunctivitis treatment industry. This conjunctivitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjunctivitis treatment market consists of revenues earned by entities by providing antibiotic therapy and eye-warming therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The conjunctivitis treatment market also includes sales of eye drops, ointments, ophthalmic steroids, non-steroidal anti-inflammatory drugs, and antihistamines, which are used in conjunctivitis treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.